RAMSEY, N.J. and BOCA RATON, Fla., March 05, 2024 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA" or the "Company"), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty biologics, today announced Adam Grossman, President and Chief Executive Officer, will participate in a fireside chat at the Raymond James Institutional Investor Conference on March 6, 2024, at 11:35 a.m. ET. A live audio webcast of the call will be available under ...

When it comes to short-term investing or trading, they say "the trend is your friend." And there's no denying that this is the most profitable strategy. But making sure of the sustainability of a trend to profit from it is easier said than done.Often, the direction of a stock's price movement reverses quickly after taking a position in it, making investors incur a short-term capital loss. So, it's important to ensure that there are enough factors -- such as sound fundamentals, positive earnings estimate rev ...

Core Insights - Healthy cash flow is essential for a company's existence, development, and success, providing strength and flexibility for investment decisions [1] - Companies with irregular cash flow, even if profitable, risk bankruptcy, making cash flow a critical measure of resilience [1][2] - Amid global economic uncertainties, analyzing cash-generating efficiency has become increasingly relevant [2] Cash Flow Analysis - Net cash flow is crucial as it indicates the actual money a company generates, impacting its ability to meet obligations and reinvest [2] - Positive cash flow signifies an increase in liquid assets, while negative cash flow indicates declining liquidity and reduced operational flexibility [2] Growth and Management Efficiency - A company must not only have positive cash flow but also increasing cash flow to demonstrate management efficiency and reduced dependency on external financing [3] Screening Parameters - Stocks were screened for those with cash flow in the latest quarter at least equal to the 5-year average, indicating a positive trend [4] - Additional criteria included Zacks Rank 1, Average Broker Rating 1, current price greater than or equal to $5, and a VGM Score of B or better [4] Stock Picks - **Griffon Corporation (GFF)**: A diversified management and holding company with a revised earnings estimate of $4.80 for fiscal 2024, up 3.9% [5] - **HNI Corporation (HNI)**: A leading provider of office furniture with a revised earnings estimate of $2.93 for 2024, up 6.5% [6] - **ADMA Biologics (ADMA)**: A biopharmaceutical company with a revised earnings estimate of $0.25 for the current year, up 13.6% [6] - **First Bank (FRBA)**: A state-chartered bank with an expected earnings growth rate of 7.9% for 2024 and a revised earnings estimate up 5.4% [7]

Shares of Adma Biologics (ADMA) have gained 1.1% over the past four weeks to close the last trading session at $5.36, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $6.88 indicates a potential upside of 28.4%.The mean estimate comprises four short-term price targets with a standard deviation of $1.44. While the lowest estimate of $6 indicates an 11.9% increase from the current ...

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price. Do they really matter, though?Let's take a look at what these Wall Street heavyweights have to say about Adma Biologics (ADMA) before we discuss the reliability of brokerage recommendations and how to use them to your advantage.Adma Biologics currently ha ...

ADMA Biologics, Inc. (NASDAQ:ADMA) Q4 2023 Earnings Conference Call February 28, 2024 4:30 PM ET Company Participants Skyler Bloom - Senior Director, Business Development and Corporate Strategy Adam Grossman - President and CEO Brian Lenz - Executive Vice President, Chief Financial Officer and General Manager, ADMA BioCenters Conference Call Participants Anthony Petrone - Mizuho Kristen Kluska - Cantor Fitzgerald Gary Nachman - Raymond James Operator Good afternoon. And welcome to the ADMA Biologics Fourth ...

RAMSEY, N.J. and BOCA RATON, Fla., Feb. 28, 2024 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA" or the "Company"), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics, today announced that Brian Lenz, Executive Vice President, Chief Financial Officer & General Manager, ADMA BioCenters will be transitioning from these positions to a consulting role, effective April 1, 2024. "On behalf of ADMA's Board of Directors and myse ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to _________ Commission File Number: 001-36728 ADMA BIOLOGICS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 56-2590442 (State or Other Jur ...

In the latest market close, Adma Biologics (ADMA) reached $5.18, with a +0.58% movement compared to the previous day. This change outpaced the S&P 500's 0.13% gain on the day. Elsewhere, the Dow gained 0.13%, while the tech-heavy Nasdaq lost 0.32%.Heading into today, shares of the infectious disease drug developer had lost 2.28% over the past month, lagging the Medical sector's gain of 3.87% and the S&P 500's gain of 2.99% in that time.The investment community will be paying close attention to the earnings ...

Adma Biologics (ADMA) closed the latest trading day at $5.40, indicating a +1.31% change from the previous session's end. The stock outperformed the S&P 500, which registered a daily gain of 0.58%. At the same time, the Dow added 0.91%, and the tech-heavy Nasdaq gained 0.3%.The infectious disease drug developer's shares have seen an increase of 8.11% over the last month, surpassing the Medical sector's gain of 2.39% and the S&P 500's gain of 4.61%.Market participants will be closely following the financial ...